Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
9.72
-0.42 (-4.14%)
Nov 3, 2025, 4:00 PM EST - Market closed
Arvinas Employees
Arvinas had 430 employees as of December 31, 2024. The number of employees decreased by 15 or -3.37% compared to the previous year.
Employees
430
Change (1Y)
-15
Growth (1Y)
-3.37%
Revenue / Employee
$866,977
Profits / Employee
-$168,837
Market Cap
713.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | 179 | 46 | 34.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARVN News
- 6 hours ago - Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 15 hours ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 days ago - Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 10 days ago - Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 12 days ago - Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 14 days ago - Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy - GlobeNewsWire
- 21 days ago - Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress - GlobeNewsWire
- 4 weeks ago - Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire